Thursday November 22, 2018 04:03

Heathcare Press Release : 12 Sep 2018

Photo Release: CGH Group Hospital held the event Happy Life with Healthy Bone and Joints Seminar in Yangon, Myanmar. Heathcare—12 Sep 18

CGH Group Hospital recently held a live health talk in Yangon, Myanmar to highlight the important health issues on bone and joints for all Myanmar people. A team of medical experts led by Dr. Wanchai Sirisereewan (4th from left), CGH's Orthopedic Surgeon

BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study Heathcare—12 Sep 18

DARMSTADT, Germany and NEW YORK--12 Sep--PRNewswire/InfoQuest
Not intended for US, Canada and UK-based media

Merck and Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the pivotal Phase III JAVELIN Renal 101 study evaluating BAVENCIO(R) (avelumab)* in combination with INLYTA(R) (axitinib)*, compared with SUTENT(R) (sunitinib) as initial therapy for patients with advanced renal cell carcinoma (RCC). As part of a planned interim analysis, an independent Data Monitoring Committee confirmed that the trial showed a statistically significant improvement in progression-free survival (PFS) by central review for patients treated with the combination whose tumors had programmed death ligand-1?positive (PD-L1+) expression greater than 1% (primary objective), as well as in the entire study populati